Navigation Links
Avaxia Biologics Elects Christopher Kiritsy to its Board of Directors
Date:4/26/2012

LEXINGTON, Mass., April 26, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has elected Christopher Kiritsy, President and Chief Executive Officer of Arisaph Pharmaceuticals, Inc. to its Board of Directors.

"I am pleased that Chris has agreed to serve on our Board," said Dr. Barbara Fox, founder, CEO and a member of the Board of Avaxia.  "As we position the company for our next phase of growth that includes manufacturing clinical materials for our inflammatory bowel disease (IBD) program and initiating our Phase I clinical trial in IBD later this year, Christopher's broad experience in building young biotech companies, his strong insight into product development and his financial expertise will be invaluable."  

About Christopher Kiritsy:
Mr. Kiritsy is a co-founder and President and Chief Executive Officer of Arisaph Pharmaceuticals, Inc. and has served as a Director since inception.  Mr. Kiritsy is a seasoned entrepreneur, who possesses 20+ years of business and technical experience, previously holding senior management positions in R&D, business development and finance.  At Arisaph, Mr. Kiritsy has evolved the organization from an academic, research orientation to a clinical development enterprise with a rich research pipeline, which led to one of the highest awards from the U.S. government's Therapeutics Discovery Project Program totaling nearly $3 million with all 12 projects funded.  Additionally, Mr. Kiritsy has executed multiple business development transactions, leveraging Arisaph's strong IP to raise in excess of 70% of its total capital from non-dilutive sources.

Prior to Arisaph, Mr. Kiritsy served as Executive Vice President, Corporate Development and Chief Financial Officer of Kos Pharmaceuticals, Inc., where he played a central role in commercializing Kos' successful Niaspan® franchise and in building the company from start-up to highly profitable, 1,200 person, fully-integrated enterprise.  During his tenure at Kos, Mr. Kiritsy raised approximately $500 million in public equity capital, including Kos' IPO, and spearheaded in excess of 10 major corporate development transactions. In 2005, Fortune Magazine ranked Kos the fastest growing pharmaceutical company in the U.S. and, in 2006, Kos was acquired by Abbott Laboratories for ~$4 billion.

Prior to Kos, Mr. Kiritsy served as Associate Director of Product Development at the Institute of Molecular Biology where he co-authored several scientific journal articles.   Mr. Kiritsy received an A.B. from Bowdoin College in Biology and an M.B.A. from Boston University.

About Avaxia Biologics, Inc.:
Avaxia Biologics is a development-stage company developing oral antibody therapeutics that act locally within the gastrointestinal tract.  The antibodies are designed to treat both diseases of the GI tract and metabolic diseases.  Using its proprietary antibody platform, Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes and obesity.


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
2. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
3. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
4. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
5. CMC Biologics Highlights Technical Acumen at Upcoming Conferences
6. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
7. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
8. Adeona Becomes Synthetic Biologics, Inc.
9. Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round
10. CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems
11. Bacterin Becomes Premier Founding Sponsor of RMECs New Osteobiologics Registry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... ... 2016 , ... Velocity Products, a division of Morris Group, ... exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, IMTS, ... companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity SMART ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
Breaking Biology News(10 mins):